65,437 trials
Myoclonus Epilepsies, Progressive
Primary: Number of Participants With Treatment-Related Adverse Events After Single Dose Treatment of AUT00201 Compared to Placebo — 5; 5 Participants
Infertility, Female
Primary: Live Birth Rate — 171; 139 Participants — p=0.042
Cognitive Dysfunction · Mild Cognitive Impairment
Primary: Usability of VR Exercises as Measured by an Adapted 8-Item System Usability Scale (SUS) — 81.9 score on a scale from 0-100
Parkinson Disease
Primary: Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser…
Acute Myeloid Leukemia · Acute Lymphoid Leukemia
Primary: Number of Participants According to Health Insurance Type — 265; 44; 253; 27 Participants
Healthy
Primary: Percentage of Subjects With Drug- Related Adverse Event — 0.0; 16.7; 50.0; 0.0 Percentage
Occupational Therapy · Virtual Reality
Primary: Pre Intervention Fugl-Meyer Assessment of Upper Extremity Motor Function (FMUE) — 42.22; 42.44 score on a scale
Postoperative Dental Pain
Primary: Sum of Pain Intensity Difference (SPID) Over 8 Hours Post-dose — 31.293; 37.242; 31.082; 5.146 Points on scale — p== 0.004
Polycystic Ovarian Syndrome · Obesity · Hepatic Steatosis
Primary: Hepatic Fat Fraction — 8; 7.3 percent hepatic fat
Treatment Resistant Depression
Primary: Change From Baseline Montgomery Asberg Depression Rating Scale (MADRS) — 40.0; 5.7 score on a scale
Presbyopia
Primary: Binocular Uncorrected Near (40 cm) Visual Acuity — 0.21; 0.39 logMAR
Alcohol Use Disorder · Cigarette Smoking
Primary: Change in Alcohol Consumed — -32.72; -6.95 grams
Ureteral Stone
Primary: Temperature Profiles — 32.5; 35.3; 37.9; 40.0 Degrees Celcius
Compliance, Patient
Primary: Urine Flow Rate — 5.43; 5.47; 2.88 mL per second
Hearing Loss, Sensorineural · Hearing Loss, Bilateral
Primary: Streaming Sound Quality Ratings — 10.7; 9.41; 7.46; 5.91 Mean Preference Counts per Participant — p=<0.001